A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth |
| |
Authors: | Seiji Kawa Hirokazu Ohbayashi Tadashi Yamamoto |
| |
Institution: | a Division of Oncology, Institute of Medical Science, University of Tokyo, Shirokanedai 4-6-1, Minato-ku, Tokyo 108-8639, Japan b Department of Research and Development, Nichirei Biosciences Inc., Tokyo 104-8402, Japan c Department of Life Science and Medical Bio-Science, School of Science and Engineering, Waseda University, Tokyo 169-8555, Japan |
| |
Abstract: | Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC50 values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab. |
| |
Keywords: | 6G10 ErbB2 Trastuzumab Breast cancer Molecular therapeutics Preclinical study |
本文献已被 ScienceDirect 等数据库收录! |
|